Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Keytruda

(pembrolizumab)

4 ML pembrolizumab 25 MG/ML Injection [Keytruda]pembrolizumab 50 MG Injection [Keytruda]

NO BLACK BOX WARNING

Dosage & administration

* Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* NSCLC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* cHL or PMBCL: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* Urothelial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MSI-H or dMMR Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* MSI-H or dMMR CRC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MSI-H or dMMR Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* HCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MCC: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* RCC: 200 mg every 3 weeks or 400 mg every 6 weeks as a single agent in the adjuvant setting, or in the advanced setting with either:
* axitinib 5 mg orally twice daily or
* lenvatinib 20 mg orally once daily.

* Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with lenvatinib 20 mg orally once daily.
* TMB-H Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* cSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* TNBC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Administer KEYTRUDA as an intravenous infusion over 30 minutes after dilution.
* See Full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions.

eficacy, safety & testing

Keytruda clinical details

Mechanism of Action (MOA)

PD-L1 Testing

MSI/MMR Testing

TMB Testing

Dosing

Preparation, Storage & Administration

Dose Modifications

Selected Adverse Reactions

Treatment Monitoring & Management

Efficacy: Advanced Melanoma

Safety Profile: Advanced Melanoma

Efficacy: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma

Safety Profile: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma

Efficacy: First-line Combination Therapy in Nonsquamous mNSCLC

Safety Profile: First-line Combination Therapy in Nonsquamous mNSCLC

Efficacy: First-line Combination Therapy in Squamous mNSCLC

Safety Profile: First-line Combination Therapy in Squamous mNSCLC

Efficacy: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC

Safety Profile: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC

Efficacy: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC

Safety Profile: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC

Efficacy: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC

Safety Profile: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC

Efficacy: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC

Safety Profile: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC

Efficacy: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Safety Profile: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Efficacy: Refractory or Relapsed PMBCL

Safety Profile: Refractory or Relapsed PMBCL

Efficacy: First-line Monotherapy for Advanced Urothelial Carcinoma

Safety Profile: First-line Monotherapy for Advanced Urothelial Carcinoma

Efficacy: Second-line Monotherapy—Post–Platinum Failure

Safety Profile: Second-line Monotherapy—Post–Platinum Failure

Efficacy: High-Risk Non-muscle Invasive Bladder Cancer

Safety Profile: High-Risk Non-muscle Invasive Bladder Cancer

Efficacy: Advanced MSI⁠-⁠H/dMMR Cancers

Safety Profile: Advanced MSI⁠-⁠H/dMMR Cancers

Efficacy: Advanced Gastric or GEJ Cancer

Safety Profile: Advanced Gastric or GEJ Cancer

Efficacy: Advanced MSI⁠-⁠H/dMMR CRC

Safety Profile: Advanced MSI⁠-⁠H/dMMR CRC

Efficacy: Advanced Esophageal or GEJ Carcinoma

Safety Profile: Advanced Esophageal or GEJ Carcinoma

Efficacy: First-line Combination Therapy for Advanced Cervical Cancer

Safety Profile: First-line Combination Therapy for Advanced Cervical Cancer

Efficacy: Second-line Monotherapy for Advanced Cervical Cancer

Safety Profile: Second-line Monotherapy for Advanced Cervical Cancer

Efficacy: Advanced Merkel Cell Carcinoma

Safety Profile: Advanced Merkel Cell Carcinoma

Efficacy: Adjuvant Treatment for Renal Cell Carcinoma

Safety Profile: Adjuvant Treatment for Renal Cell Carcinoma

Efficacy: Advanced Renal Cell Carcinoma

Safety Profile: Advanced Renal Cell Carcinoma

drug label

Keytruda prescribing information

Have more Keytruda questions?

Submit MSL Request

Learn More

Need to report a Keytruda issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Keytruda Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

Coverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

2022 Merck Access Program Enrollment Form

2023 Merck Access Program Enrollment Form

Merck Access Program - 2023 Healthcare Provider Enrollment Form

2022 Merck Access Program Electronic Enrollment Form

2023 Merck Access Program Electronic Enrollment Form

Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Keytruda Financial assistance options

Co-pay savings program

commercial only

2022 Merck Access Program Enrollment Form

2023 Merck Access Program Enrollment Form

Merck Access Program - 2023 Healthcare Provider Enrollment Form

2022 Merck Access Program Electronic Enrollment Form

2023 Merck Access Program Electronic Enrollment Form

Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

2022 Merck Access Program Enrollment Form

2023 Merck Access Program Enrollment Form

Merck Access Program - 2023 Healthcare Provider Enrollment Form

2022 Merck Access Program Electronic Enrollment Form

2023 Merck Access Program Electronic Enrollment Form

Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form

Merck Patient Assistance Program Application

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Keytruda Patient education

Getting started on Keytruda

NOT PROVIDED BY BRANDInstructions For Use: Advanced Melanoma

NOT PROVIDED BY BRANDInstructions For Use: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma

NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy in Nonsquamous mNSCLC

NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy in Squamous mNSCLC

NOT PROVIDED BY BRANDInstructions For Use: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC

NOT PROVIDED BY BRANDInstructions For Use: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC

NOT PROVIDED BY BRANDInstructions For Use: Subsequent-line Monotherapy in Recurrent or Metastatic HNSCC

NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC

NOT PROVIDED BY BRANDInstructions For Use: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC

NOT PROVIDED BY BRANDInstructions For Use: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

NOT PROVIDED BY BRANDInstructions For Use: Refractory or Relapsed PMBCL

NOT PROVIDED BY BRANDInstructions For Use: First-line Monotherapy for Advanced Urothelial Carcinoma

NOT PROVIDED BY BRANDInstructions For Use: Second-line Monotherapy—Post–Platinum Failure

NOT PROVIDED BY BRANDInstructions For Use: High-Risk Non-muscle Invasive Bladder Cancer

NOT PROVIDED BY BRANDInstructions For Use: Advanced MSI⁠-⁠H/dMMR Cancers

NOT PROVIDED BY BRANDInstructions For Use: Advanced Gastric or GEJ Cancer

NOT PROVIDED BY BRANDInstructions For Use: Advanced MSI⁠-⁠H/dMMR CRC

NOT PROVIDED BY BRANDInstructions For Use: Advanced Esophageal or GEJ Carcinoma

NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy for Advanced Cervical Cancer

NOT PROVIDED BY BRANDInstructions For Use: Second-line Monotherapy for Advanced Cervical Cancer

NOT PROVIDED BY BRANDInstructions For Use: Advanced Hepatocellular Carcinoma

NOT PROVIDED BY BRANDInstructions For Use: Advanced Merkel Cell Carcinoma

NOT PROVIDED BY BRANDInstructions For Use: Adjuvant Treatment for Renal Cell Carcinoma

Patient toolkit

NOT PROVIDED BY BRANDNot Provided By Brand

Learn More

Keytruda FAQs

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:

Please note:

Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.

Keytruda

Dosage & administration

eficacy, safety & testing

Keytruda clinical details

drug label

Keytruda prescribing information

Have more Keytruda questions?

Need to report a Keytruda issue?

prior authorization

Keytruda Prior authorization resources

Benefits investigation

Reimbursement help (FRM)

financial assistance

Keytruda Financial assistance options

Co-pay savings program

Bridge program

Foundation programs

patient education

Keytruda Patient education

Getting started on Keytruda

Patient toolkit

people also ask

Keytruda FAQs

Can't find what you're looking for?